Advances in effective antiretroviral therapy for HIV infection have made high-dose therapy and autologous stem cell transplantation possible in patients with HIVassociated lymphomas. Regimen-related toxicity is not significantly increased when antiretroviral therapy is combined with high-dose chemoradiotherapy. Durable engraftment can be seen with autologous stem cell rescue. Infectious complications can be managed with a combination of surveillance and prophylaxis. Long-term remissions of these high-risk lymphomas can be achieved with this approach. This suggests that patients with HIVassociated lymphomas should be considered for autologous transplantation in a manner similar to HIV-negative lymphoma patients Bone Marrow Transplantation (2003) 32, 741-748.
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The advent of highly active antiretroviral therapy (HAART) has led to new treatment options for patients with HIV and other concurrent medical conditions either related or unrelated to their HIV infection. For example, centers in several states are now performing solid organ transplants in HIV-positive individuals with life-threatening end-stage organ disease who fulfill the other requisite criteria for renal or liver transplantation. 1 This brings to the forefront the question for bone marrow transplant centers: should we routinely consider high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) for patients with HIV infection and lymphoma?
Clinical features of HIV-associated lymphomas
It has long been recognized that the incidence of nonHodgkin's lymphoma (NHL) is increased in HIV-infected individuals and is considered an AIDS-defining illness. 2 Moreover, recently we have come to recognize that Hodgkin's (HD) lymphoma is also increased in incidence in HIV-infected patients. 3 When these lymphomas occur in association with HIV infection, they tend to present with an advanced stage, B symptoms, extranodal sites of disease and commonly bone marrow involvement. [4] [5] [6] Prognostic factors associated with shortened survival for HIV-associated NHL include age 435 years, a history of intravenous drug abuse, stage III or IV disease, CD4 counts o100 and an elevated LDH. 7 In addition, the international prognostic index has been found to be highly correlated with survival. 8 Historically, prior to effective antiretroviral therapy, the treatment of both HIV-NHL and HD was hampered by high rates of opportunistic infections (OIs) and cytopenias from the underlying HIV infection. This led to the early treatment paradigm that less intensive chemotherapy was sufficient and less toxic. 9 However, the results with either conventional or dose-reduced treatment were poor and far worse than in the HIV-negative lymphoma setting. 9, 10 For example, in the AIDS Clinical Trial Group study of lowdose M-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone) vs conventional dose M-BACOD, the median survival was only 35 and 31 weeks, respectively. Similarly for HIV-HD, a trial using standard-dose ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) with growth factor support resulted in neutropenia in approximately 50% of the patients with a median survival of only 18 months. 11 Treatment options for relapsed HIV-related HD or NHL are even more limited, with the majority of studies reporting median survivals of only 3-7 months. 12, 13 Thus, new treatment strategies such as ASCT are worthy of further study in these high-risk lymphomas.
Effects of HAART

Does HAART lower the incidence of HIV lymphoma?
HAART changed the course of HIV infection by increasing CD4 counts, reducing the incidence of OIs and ultimately prolonging survival (Table 1). 14 It is also clear that HAART has reduced the incidence of Kaposi's sarcoma and primary CNS lymphoma. 15 The effects on other lymphomas are less clear. A large multicenter European study showed a decrease in the proportion of new AIDS cases due to OIs in the era of HAART, but an increase in the proportion of new AIDS secondary to lymphoma. 16 In contrast, an international collaborative study combining data from over 20 trials did show a reduction in the lymphoma incidence from the pre HAART era (1992) (1993) (1994) (1995) (1996) vs 1997-1999. Of note, the incidence of immunoblastic and primary CNS lymphoma declined most significantly, while there was no decline in the incidence of Burkitt's lymphoma or HD.
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Can we combine HAART with chemotherapy?
The improvement in immune function and hematologic reserve with HAART has led to interest in its use in combination with antilymphoma chemotherapy. An AIDS malignancy consortium study combined a HAART regimen of stavudine, lamivudine and indinavir with either standard-or reduced-dose CHOP (cyclophosphamide, adriamycin, vincristine, prednisone). Cyclophosphamide clearance was reduced in patients on concomitant HAART when compared to historical controls. However, no clinical consequences from this were apparent. 18 Other studies have suggested an increase in neurotoxicity when CHOP is combined with HAART (13% in the HAART group vs 0% in the no-HAART group), but this has not been dose limiting. 19 One study also raises the concern of increased mucositis when combining infusional chemotherapy CDE (cyclophosphamide, doxorubicin, etoposide) with nucleoside analogues. 20 Furthermore, a recent study evaluating immune parameters of patients on concomitant HAART and chemotherapy demonstrated that patients can maintain an undetectable viral load and recover CD4 counts to baseline after completion of chemotherapy. 21 Similarly in HIV-HD, the combination of conventional chemotherapy regimens with HAART has been well tolerated and may even lead to improved survival. For example, an Italian study combined the multidrug Stanford V regimen with HAART, and a complete remission rate of 81% was achieved with an estimated 3-year survival of 51%. 22 An alternate approach has been taken by investigators at the NCI in which HAART was temporarily suspended during the time of chemotherapy. They utilized infusional EPOCH (etoposide, vincristine, cyclophosphamide, doxorubicin, prednisone) with growth factor support. All antiretroviral therapy was held until day 6 of the last dose of chemotherapy. Despite an increase in HIV viral loads up to 1000-fold by cycle 4 of therapy, within 3 months of restarting HAART, the viral load returned to pretreatment levels. CD4 counts recovered by 12-24 months post treatment, and no increase in OIs was seen. The initial CR rates are impressive at 79%, with no CR patient thus far having relapsed. 23 Thus, most studies suggest that HAART can be combined with chemotherapy in various ways. The use of concomitant therapies may improve CR rates and lead to improved survival. Attention should be paid to increased neurotoxicity. In addition, it is prudent to avoid HAART regimens containing potentially highly myelosuppressive agents such as zidovudine (AZT) and others, such as lamivudine, which are potentially myelosuppressive.
HDC and HAART
Randomized trials have demonstrated that HDC with ASCT improves overall survival over conventional dose salvage therapy for patients with relapsed NHL. 24, 25 Similarly, for patients with relapsed HD, this approach has demonstrated improved disease-free survival. 26 As the upfront mortality of ASCT has significantly decreased, centers worldwide have conducted studies in HIV-negative patients with high-risk first-remission disease. 26, 27 Given the high-risk features of HIV-associated lymphomas, as well as the lack of effective salvage regimens for relapsed disease, transplant centers such as the City of Hope Comprehensive Cancer Center have explored the use of dose-intensive chemotherapy and ASCT in conjunction with HAART.
Can HIV lymphoma patients mobilize stem cells?
The ability to mobilize stem cells was the first theoretical hurdle to ASCT in HIV-positive patients. The presence of multilineage cytopenias in HIV-infected individuals suggests that the effects of the virus on marrow suppression are more far reaching than on the T-cell subsets only. Alterations in the bone marrow microenvironment and the cytokine milieu are some of the postulated mechanisms. 28, 29 Of note, several experimental models have demonstrated that primitive hematopoietic progenitor cells are not directly infected by the virus, although their functioning can be disturbed by the presence of the virus. 29 HAART has favorable effects on the hematologic reserves, as demonstrated by increases in white blood cell and platelet counts as viral loads decline. 30 Therefore, with the advent of effective antiretroviral regimens, stem cell mobilization in HIV-infected patients became possible. Furthermore, studies from our institution found no longterm deleterious effects of the GCSF used for mobilization on the HIV viral load, and in addition demonstrated the potential of these apheresed stem cells to differentiate and produce normal numbers of hematopoietic cells. 31 In patients with HIV and lymphoma, we used the last cycle of lymphoma chemotherapy as the mobilizing regimen followed by GCSF (10 mg/kg/day). We discontinued trimethoprim-sulfamethoxasole (TMP-SMX) during this period to avoid possible myelosuppression. A total of 19 patients have undergone apheresis with a median of 10.5 Â 10 6 CD34 þ cells/kg collected. The reason for this relatively high number is that five patients had additional stem cells collected as part of a gene therapy trial. We process the cells in the same manner as HIV-negative Table 1 Effects of HAART on NHL Stem cell transplants for HIV-positive lymphoma patients products using 'universal precautions'. The products are stored in a separate designated freezer and labeled as an HIV-positive unit. In this series, 16 patients were on a non-AZT HAART regimen and mobilized stem cells in a time course similar to our HIV-negative lymphoma patients. Three recent patients were on an AZT combination regimen as part of Trizivir or Combivir (Table 2 ) and one experienced significant difficulty with mobilization requiring 10 days of apheresis and one had delayed engraftment. We, therefore now recommend that all patients be switched from AZT to an alternate antiretroviral medication during chemotherapy and apheresis.
Is there increased toxicity when we combine HAART and HDC?
As we previously mentioned, there has been great concern about increased organ toxicity due to the protease inhibitors inhibiting specific cytochrome P-450 enzymes that are important for chemotherapy metabolism. In a case report of solid organ transplantation in a patient with HIV, the patient developed seizures from supratherapeutic levels of immunosuppressive medications in part due to impaired metabolism of these medications due to his HIV antiretroviral regimen. 32 The increased neurotoxicity and hepatotoxicity seen with concomitant HAART and conventional dose chemotherapy may be of further concern in the high-dose setting. 19, 20 We have transplanted a total of 19 HIV lymphoma patients (see Table 2 ) with either a chemotherapy-based regimen of CBV (cyclophosphamide 100 mg/kg, carmustine 450 mg/m 2 , etoposide 60 mg/kg) in 16 or a radiotherapybased regimen of total body irradiation (TBI) 1200 cGy, cyclophosphamide 100 mg/kg, etoposide 60 mg/kg in three. Patients were maintained on HAART throughout the transplant if possible, although 10 were intolerant due to gastrointestinal toxicity, such as either nausea, vomiting or mucositis. All patients did develop hepatotoxicity, although in the majority it was grade 1-2. Three patients developed grade 3-4 hepatotoxicity -two due to the conditioning regimen, one ultimately died of multiorgan failure at day þ 22 post transplant. The third patient had late hepatotoxicity at 10 months post ASCT that was ultimately ascribed to his antiretroviral regimen as it resolved when these medications were discontinued. No patient developed neurotoxicity. Severe mucositis was seen in the patients receiving TBI, which is an expected complication of this regimen.
Similarly, investigators from France have reported their ASCT experience in 14 patients with HIV lymphoma (Table 3) . Eight received an FTBI-based regimen and six received a chemotherapy-based regimen. Regimen-related toxicities were not reported to be increased over the HIVnegative setting. 33 Other centers have transplanted smaller numbers of patients with a variety of conditioning regimens including nonmyeloablative regimens. [34] [35] [36] The overall trend is similar in that engraftment was achieved and only transient increases in HIV viral load were observed (Table 3) . [34] [35] [36] In the 19 patients from the City of Hope series, the median time to neutrophil engraftment was 11 days (range 9-23), a time course similar to the HIV-negative patients. However, one of the recent patients in our series (UPN416) was maintained on his AZT combination regimen during the transplant. It is our impression that this led to the marked delays in his engraftment. White cell engraftment was at 23 35 found delayed engraftment in both platelets and neutrophils in the HIV-positive lymphoma patients when compared to an HIV-negative cohort. However, details of the HAART regimen used are not provided.
Can we perform ASCT without increasing AIDS-related complications?
Another initial barrier to transplantation in HIV-infected patients was the concern that the increased immunosuppression from the transplant may ultimately lead to early mortality from OIs. Certainly, the early transplant experience prior to HAART demonstrated exactly that problem. 37 However, with current treatment options and appropriate prophylaxis against OI, no patient in our series died of an infectious complication. In our protocol, patients are maintained on pentamidine for pneumocystis (PCP) prophylaxis during apheresis. During the transplant, levofloxacin is started at day À9 for gut decontamination and TMP-SMX is also used from days À9 to À2 for PCP prophylaxis. Intravenous acyclovir is used for herpes prophylaxis and either low-dose amphotericin (0.15 mg/ kg) or fluconazole 200 mg/day is used for antifungal prophylaxis. After engraftment, we continue TMP-SMX and also use high-dose oral acyclovir for zoster prophylaxis for 1-year post ASCT. In addition, azithromycin is used for Mycobacterium avium complex prophylaxis until CD4 counts have reached stable levels. Lastly, surveillance cultures for cytomegalovirus are performed weekly until day þ 100 (see Table 4 ).
With this strategy, infectious complications pre engraftment were similar to HIV-negative patients, with Gram-positive bacteremias predominating. Two patients developed a fulminant engraftment syndrome-type picture with high fevers and skin rashes and negative blood cultures. This responded to steroids. Post engraftment, the most serious infections were respiratory with four patients developing bacterial pneumonias. In the patients with frequent respiratory infections, we now also check immunoglobulin levels for the first year post transplant and give replacement therapy as needed.
Five patients did develop OIs. Two patients developed PCP pneumonia. Although of note, both these patients were not compliant with prophylaxis. One of these patients also developed CMV retinitis and the other soon after his PCP pneumonia developed Aspergillus pneumonia. This was presumed to be from the steroids required for his PCP pneumonia therapy. He is currently on outpatient antifungal therapy and appears to be responding. One patient developed disseminated herpes zoster, which was prior to our routine use of acyclovir prophylaxis post ASCT. One patient developed CMV viremia and low-grade fevers at day þ 37 that responded to therapy and one patient developed asymptomatic CMV viremia that did not require treatment. Similarly, in the French series, two patients developed CMV viremia post ASCT not associated with organ-specific disease 33 ( Table 3) . Also of note, in the nonmyeloablative transplant series of two patients, both developed CMV viremia and one developed central nervous system toxoplasmosis. 34 Hence, our feeling is that infectious complications are a concern but can be minimized with an appropriate strategy of close surveillance and prophylaxis.
What happens to the HIV infection during and after the transplant?
Another concern with an autologous transplant strategy was recovery of CD4 counts and effects on the HIV viral load. Specifically, are we curing the lymphoma but at the price of worsening the HIV infection?
In an attempt to optimize control of the HIV infection, we attempted to continue HAART during the transplant. The hope was that control of viral replication would allow engraftment and minimize infectious risks. We initially had no restrictions on the type of antiretroviral regimen used. However, after the prolonged engraftment seen in patients on zidovudine, we now prohibit its use either as a single agent or as a combination pill (Trizivir, Combivir). A large portion of our patients and those in the French series were on stavudine, a nucleoside analogue, which is generally well tolerated except for mild nausea. Its absorption is not affected by meals and it has no significant drug interactions. These patients were also often taking the nucleoside analogue lamivudine, which similarly has no reported drug interactions and is rapidly absorbed after oral administration. In terms of protease inhibitors, patients were taking either saquinavir, indinavir or ritonavir. Saquinavir has limited bioavailability. The major concern in the setting of Table 4 Practice points to remember
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Assess viral load (o10 000 copies/ml preferred) Stem cell transplants for HIV-positive lymphoma patients A Krishnan et al the transplant is that it is metabolized by the cytochrome P-450 system. Therefore P-450, 3A4 inhibitors may raise levels of saquinavir. In contrast, saquinavir inhibits P-450CYP3A and therefore, it may elevate plasma concentrations of drugs metabolized by this enzyme such as midazolam and triazolam. Similarly, the other protease inhibitors indinavir and ritonavir have inhibitory effects on the P-450CYP3A system and therefore, comparable drug interactions to saquinavir. Despite the attempt to continue HAART, in fact, the majority of patients were unable to tolerate it during the transplant due to either nausea or mucositis. If patients miss doses due to nausea, we do not advocate redosing. If patients missed many doses, we subsequently discontinued therapy until recovery from the transplant rather than continuing an intermittent erratic dosing schedule. As expected, CD4 counts did nadir post ASCT in all patients on or off HAART. This was seen at a median of 4.5 months in eight patients. The majority of patients did recover CD4 counts by 1 year post ASCT (Figure 1 ). Two patients have not yet recovered their counts and three died before CD4 recovery. We saw transient increases in the viral load in the first 2 months post transplant in the majority of patients. We saw persistent elevations in viral load in three patients who were noncompliant with HAART. One patient who was compliant still required multiple changes in his regimen due to resistance. In the French series, there were transient increases in viral load in two of nine patients with previously undetectable viral loads. Although of note, there was no statistically significant difference in viral load or CD4 count pre and post ASCT for the 14 patients. 30 In the nonmyeloablative allotransplant series, one patient had an abrupt rise in viral load to 10 6 copies/ml during a period off HAART. Resumption of antiretroviral therapy returned viral loads to undetectable levels. In the Spanish series, they report no increase in viral load with BMT conditioning as long as HAART is maintained. 35 It has been our observation that we have not seen long-term deleterious effects of ASCT in patients who are compliant with HAART. However, this also bespeaks to the need to evaluate patients closely pre ASCT with regard to their ability to comply with their antiretroviral therapy in order to optimize outcome from the transplant.
Can we cure HIV lymphoma with ASCT?
In our series of 19 patients, three have died: two from relapsed lymphoma early post ASCT and one from regimen related toxicity. In all, 16 patients are alive and in remission with a median follow-up of 27.5 months (6-57.5 months) (Figure 2) .
In the French cohort, six patients died from relapsed lymphoma, one from AIDS and one from a second malignancy. Details of the extent of prior therapy of these patients were not published; however, one can postulate that the more favorable results from our series may in part be due to the earlier use of transplantation. Many of the French cohorts had more advanced disease as well as chemotherapy refractory disease. In contrast, the Serrano series includes first CR patients, and all patients remain in remission, although follow-up is short. We have attempted to utilize the same criteria that we use for HIV-negative lymphoma patients evaluated for transplant, for example, chemosensitive, disease or high-risk first remission disease. Of note, the majority of our patients had relapsed lymphoma or failed to achieve a remission despite the upfront use of conventional chemotherapy and HAART. Hence, one cannot ascribe our results only to the use of HAART and its attendant improved response rates in combination with chemotherapy. The patients who died from relapse in our series had poorly controlled disease, one with an anaplastic large-cell NHL and one with Burkitt's leukemia. Hence, the use of high-dose therapy early in the course of chemotherapy responsive disease in these HIV-associated lymphomas may be of benefit.
Conclusion
In summary, high-dose therapy with autologous stem cell rescue is feasible in HIV-infected patients with lymphoma. Interactions between chemotherapy and HAART have not been a cause of significant increases in regimen-related toxicity. However, the use of AZT should be avoided as it can cause significant delays in engraftment. Infectious complications early post transplant are similar to HIVnegative patients; however, the use of appropriate prophylaxis and surveillance is necessary to minimize the risk of OIs. There appear to be no long-term deleterious effects on the HIV infection, although short-term increases in HIV viral load and expected declines in CD4 counts are seen. Lastly, the long-term remissions seen in many of these patients suggest that this modality should be considered for patients with relapsed chemosensitive disease. Thus, ASCT should be offered to patients with HIV and lymphoma. The HIV infection can be considered analogous to other chronic illnesses and should not be a barrier to transplantation. Future directions of therapy will expand upon this initial favorable experience with transplantation in multiple ways (Table 5 ). For instance, we have explored the use of highdose ibritumomab and chemotherapy with ASCT in HIVnegative patients. It has been used in 18 patients and appears to be well tolerated; therefore, expanding its use to HIV-positive lymphoma patients may be warranted. Alternately, allogeneic approaches using less dose intense regimens similar to those used in the HIV-negative setting are being explored. Lastly, studies are being initiated to explore new ways of controlling the HIV infection such as genetic modification of autologous cells or transplanting intrinsically HIV-resistant allogeneic stem cells such as those that lack the CCR5 coreceptor necessary for HIV entry into the cell. The rationale for this is that better control of the HIV infection may ultimately lead to lower chances of relapse of the lymphoma. 
